Arvelle Therapeutics is an emerging biopharmaceutical company focused on bringing treatments to patients with CNS disorders and is responsible for developing and commercializing cenobamate in Europe. The company is headquartered in Zug, Switzerland. Cenobamate was discovered by SK Biopharmaceuticals and SK life science and is approved in the U.S., where it is commercially available as XCOPRI. Arvelle holds exclusive European rights and is preparing for a potential European launch pending regulatory approval. The company plans to expand operations across Europe and make country-by-country hires in preparation for that launch. Clinical work includes open-label extensions of prior trials and an ongoing randomized, double-blind, placebo-controlled trial evaluating cenobamate in primary generalized tonic-clonic seizures (NCT03678753). Financially, Arvelle has secured substantial capital to support commercialization and operations. Arvelle Therapeutics was launched as a spin-off from Axovant Sciences to focus on bringing innovative solutions to patients with CNS disorders. The company’s lead program is cenobamate, a novel small-molecule investigational antiepileptic drug for potential treatment of partial-onset seizures in adults. Arvelle entered into an exclusive license with SK Biopharmaceuticals to develop and commercialize cenobamate in Europe and intends to file a Marketing Authorization Application (MAA) based on SK Biopharmaceuticals’ global clinical trial program. The new company assembled a leadership team from Axovant, with Mark Altmeyer named president and CEO. Arvelle received substantial initial funding from a global syndicate of biotechnology investors, enabling the licensing agreement and launch. Axovant originated and structured the cenobamate license but is not contributing capital to Arvelle’s initial financing, which is non-dilutive to Axovant shareholders.

Total raised

$142M

Funding rounds

2

Latest round

Series A

Latest activity

May 2020